Benitec Biopharma Inc (BNTC)
9.25
+0.07
(+0.76%)
USD |
NASDAQ |
May 10, 16:00
9.12
-0.13
(-1.41%)
After-Hours: 20:00
Benitec Biopharma Cash from Financing (TTM): 27.96M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 27.96M |
September 30, 2023 | 27.92M |
June 30, 2023 | 16.02M |
March 31, 2023 | 16.02M |
December 31, 2022 | 16.02M |
September 30, 2022 | 16.02M |
June 30, 2022 | 0.00 |
March 31, 2022 | 12.67M |
December 31, 2021 | 12.67M |
September 30, 2021 | 22.52M |
June 30, 2021 | |
March 31, 2021 | |
December 31, 2020 | |
September 30, 2020 |
Date | Value |
---|---|
June 30, 2020 | 1.77M |
March 31, 2020 | 8.019M |
December 31, 2019 | 8.019M |
September 30, 2019 | 8.019M |
June 30, 2018 | 6.249M |
March 31, 2018 | 0.0258M |
December 31, 2017 | 4.297M |
September 30, 2017 | 6.101M |
June 30, 2017 | 6.101M |
March 31, 2017 | 5.742M |
December 31, 2016 | 2.131M |
September 30, 2016 | 0.8506M |
June 30, 2016 | 13.08M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
Jun 2022
27.96M
Maximum
Dec 2023
13.83M
Average
14.34M
Median
Cash from Financing (TTM) Benchmarks
Galectin Therapeutics Inc | 40.03M |
TG Therapeutics Inc | 47.48M |
BioVie Inc | 15.36M |
Jaguar Health Inc | 34.23M |
First Wave BioPharma Inc | 15.23M |